For University Technology Transfer Offices
A Vantage TTO Report reads one university-held asset or spinout across its regulatory, clinical, IP and reimbursement record, with sources, and is reviewed by a physician and a biomedical engineer. Offices with many disclosures can run it as an annual program.
A busy office sees more invention disclosures than it has clinical and commercial bandwidth to read closely. A TTO Report puts the public record on one technology in front of your team — regulatory precedent, clinical evidence, the patent landscape, reimbursement and comparable companies — so the licensing call rests on documented facts. The decision stays with your office.
What a report helps answer
The report sets out what the record shows about this technology’s regulatory path, clinical evidence, patent landscape and reimbursement, and what comparable technologies faced. It is a read of one technology, not a ranking of your portfolio.
The same eight domains investors examine — regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive position — each tied to its sources.
Each TTO Report is reviewed by Arvind Ravinutala, MD, for the clinical and regulatory picture and by Aswini Ravinutala, BME, for the technology, design and manufacturing questions, with a 30-minute debrief.
An executive summary opens every report, and the findings behind it carry their sources, so leadership and faculty can check the reasoning themselves.
Use Cases
Read a disclosure’s public record before committing patent budget, so the filing decision rests on what the record and comparable technologies show.
Give a spinout’s founders an independent, cited read of the questions an investor will ask before they raise.
Show university leadership and advisory boards where a technology stands on the record, with the sources attached.
Pricing for TTOs
Start with a single technology. Offices that review many disclosures can set up an annual program, scoped with you on a call.
Commercialization readiness on one university-held asset or spinout, framed for a licensing decision.
Program-wide coverage so disclosures are read on the same consistent basis through the year. The number of reports and the timing are set with you on the call.
Screening many disclosures quickly? The Quick Screen is $5,000 per technology: automated, six independent signals linked to their source records, with no composite score or verdict. The fee credits in full toward a larger engagement. See the Quick Screen →
University purchasing. Tell us on the call how your office buys outside services, and we will work within your process where we can.
Built for Technology Transfer
An outside clinical and engineering read on a disclosure — what the record shows about its regulatory, reimbursement and commercial path — without building an internal review team.
A documented read you can put in front of your board and faculty, with the sources attached.
Delivery within 48 hours of a complete intake, so licensing decisions don’t wait on scarce internal bandwidth.
Deliverables
Every report opens with an executive summary for leadership. The sample uses an illustrative company.
See a sample report →Every report is delivered under our standard engagement terms. It is independent diligence on the public record and the materials you provide — not legal or patent advice, not investment advice and not a prediction of commercial outcomes.
Your Review Team
Arvind Ravinutala, MD, is a practicing physician and chairs a Pharmacy and Therapeutics (P&T) Committee. Aswini Ravinutala, BME, is a biomedical engineer with 10+ years in medical devices and is R&D Manager at Spiro Medical. Meet the team →
Book a free 20-minute call to talk through a technology or your office’s pipeline, and whether a single report or an annual program fits. No obligation.